Status:
UNKNOWN
Population Pharmacokinetics and Dosage Individualization of Paracetamol and Ibuprofen in Children With PDA
Lead Sponsor:
Shandong University
Collaborating Sponsors:
West China Second University Hospital
Conditions:
Patent Ductus Arteriosus
Eligibility:
All Genders
Up to 28 years
Brief Summary
The investigator's purpose is to study the population pharmacokinetics of paracatamol and ibuprofen in neonates with patent ductus arteriosus (PDA) and assess the feasibility of dosage individualizati...
Detailed Description
The investigator's purpose is to study the population pharmacokinetics of paracatamol and ibuprofen in neonates with patent ductus arteriosus (PDA) and assess the feasibility of dosage individualizati...
Eligibility Criteria
Inclusion
- Patients have been diagnosed with PDA;
- Age: postnatal age ≤ 28 days;
- Paracetamol or ibuprofen used as part of regular treatment;
- Paracetamol or ibuprofen was administered orally.
Exclusion
- Patients who die within the treatment cycle;
- Patients with other heart diseases;
- Other factors that the researcher considers unsuitable for inclusion.
Key Trial Info
Start Date :
May 25 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 6 2023
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04397913
Start Date
May 25 2020
End Date
May 6 2023
Last Update
May 21 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West China Second University Hospital
Chengdu, Sichuan, China, 610041